New dog-sized dinosaur species discovered
Scientists have discovered a new species of dinosaur — one that was dog-sized and roamed what is now the United States around 150 million years ago alongside familiar dinosaurs like stegosaurus and diplodocus.
The Enigmacursor mollyborthwickae, as researchers named it, was about the same size as a Labrador retriever, with a tail that made up about half of its length, according to a study published in the Royal Society Open Science on Wednesday.
Although many of its bones were unearthed from the Morrison Formation in Colorado in 2021-2022, its skull and parts of its vertebral column were missing, leaving scientists unsure of its precise length.
'These very small plant-eating dinosaurs are pretty rare (to find),' Professor Paul Barrett, a researcher at London's Natural History Museum who co-led the study, told CNN.
'Actually finding a substantially completed skeleton rather than a few bits and pieces of bones is not common and as a result they're fairly poorly known.'
The skeleton will be displayed at the Natural History Museum from June 26.
This dinosaur was quite 'lightly built' and weighed around the same as a collie, said Barrett. It was a herbivore and would have walked on its long hind legs, which 'suggests it was quite a speedy runner' allowing it to make a 'quick getaway' from predators, Barrett added.
He and his colleague, Susannah Maidment, began investigating this specimen after a London art gallery, which was displaying the dinosaur, got in contact with them.
They were eventually able to work with the gallery to find a donor who could help bring the skeleton to the museum. The species name honors that donor, Molly Borthwick, while the genus name is Latin for 'mysterious runner.'
By carefully examining the bones, Maidment and Barrett concluded that this specimen had unique characteristics unlike any other previously known species. In particular, its thigh bone was particularly distinctive, with different sorts of muscle attachments than other dinosaurs, Barrett said.
It is most closely related to Yandusaurus hongheenis, a three-meter- (9.8-foot) long dinosaur that has been found in China. This suggests the species was widely distributed, Barrett said, hypothesizing that other fossils of it simply haven't been found yet.
Scientists believe this specimen was not yet fully grown as some of its vertebrae had not yet fused but, because of the way the fossil was prepared before it came to the Natural History Museum, they can't be certain. It is also not clear how the dinosaur died because there aren't any obvious signs of illness or injury in its bones.
New species of dinosaurs are unearthed or identified relatively frequently, about once a week, said Barrett. But finding small dinosaurs like this is much rarer, partly because they're overlooked by fossil hunters searching for bigger, more impressive dinosaurs and partly because smaller skeletons are more likely to be ripped apart by predators and scavengers.
Finding these smaller dinosaurs which are often left in the ground 'gives us a more complete idea of what those ecosystems were like,' Barrett said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
43 minutes ago
- Forbes
Ben Lamm Represents The Potential Of Biotech, And Why We Should Keep Supporting Innovators
The rapid adoption of artificial intelligence in genetic engineering, health care, and medical research could lead to significant improvements in human health and our ecological environment in the decades ahead. But biotech innovators and entrepreneurs worldwide will have to overcome a global political environment that has suddenly become skeptical of science, expertise and public health in general. Last week, 20,000 scientists, executives, investors and startups descended upon Boston for the BIO 2025 Convention – the largest medical research and biotech convening in the world. The convening took place amidst significant opportunity – and turmoil, in health care worldwide. The rapidly expanding capabilities of artificial intelligence are unlocking new opportunities to develop new drugs, therapeutics, wearables and devices. But BIO also comes at a time of significant declines in government funding for basic science and R&D, as well as a drop in global leadership around public health challenges like pandemic preparedness. BIO 2025 Exhibition Hall In 2025, the United States is expected to announce cuts of 40-60% to the National Institutes of Health and National Science Foundation. Yet American states are offering biotech's R&D credits, seed funding, lab space and commitments to improve their workforce and academic institutions. Nations around the world, sensing opportunity, are also rolling out the red carpet to attract the top scientists in the world. BIO itself highlighted the importance of building public trust in biotechnology and working with regulatory bodies to streamline approvals for innovative products. Colossal Biosciences is a great example of a biotech startup at the intersection of these trends and challenges. Founded by legendary geneticist Dr. George Church of Harvard and MIT, and serial AI entrepreneur Ben Lamm, Colossal is pioneering the use of CRISPR technology in the de-extinction of previously lost species, including the Dire wolf. According to the International Union for the Conservation of Nature, nearly 50% of all animal species could be endangered of becoming extinct by 2050. According to Lamm, 'We are the back-up plan. It's like, when we jump out of a plane, we all hope the parachute is going to open, but just in case, we want to have a back-up emergency 'chute. Colossal is that back-up.' The company defines de-extinction as the process of generating an organism that both resembles and is genetically similar to an extinct species by resurrecting its lost lineage of core genes; engineering natural resistances; and enhancing adaptability that will allow it to thrive in today's environment of climate change, dwindling resources, disease and human interference. The Dire Wolf, as imagined by Colossal Biosciences Such ambition and optimism were pervasive across BIO. Scores of startups today are using artificial intelligence for health care delivery, hospital operations, digital health platforms, diagnostics, patient monitoring tools, revenue cycle management, and even regulatory and compliance innovations. Biotech startups are using AI to improve drug discovery, target validation and optimize clinical trials. CRISPR, the ubiquitous gene editing tool now used in drug discovery, continues to improve as more genomes are mapped. Colossal has developed a set of new software tools and technologies, along with CRISPR gene editing technology to resurrect these specific species but to also build a 'de-extinction toolkit' that can be used for difference animal species as needed. According to Chief Science Officer, Dr. Beth Shapiro, a world-renowned evolutionary molecular biologist and a leading figure in the field of ancient DNA and paleo genomics, 'we are developing a modular system that combines gene editing, cryopreservation, synthetic biology, and cloning to preserve, restore, and recreate species.' As an example, the team at Colossal uses the genetics of the used the genetics of the closet relative of the team successfully used comparative genetics with its closest living relatives, the gray wolf, to fill in critical gaps in the genetic sequence. That cloning research that came from the project has immediate impacts on red wolf conservation and will serve as a critical tool for all canid restoration in the future. The biotech industry worldwide continues to grow in importance, and no doubt there will be continued investment in the basic science, R&D and commercialization that drives important companies like Colossal and others. It is less clear whether that leadership will come from the United States or other nations – such as the United Arab Emirates, India, China, Japan or elsewhere? We don't know what areas of innovation those nations will prioritize, and whether or not important moonshots – like bringing back the woolly mammoth, will be on their radar. American leadership – scientific, political and financial, needs to remain committed to improving health of humans and the planet at large.
Medscape
2 hours ago
- Medscape
Fast Five Quiz: Risk Factors, Symptoms, & Treatments for AD
Alzheimer's disease is the most common form of dementia. Researchers believe that converging environmental, lifestyle, and genetic risk factors trigger a pathophysiologic cascade that, over decades, leads to Alzheimer's pathology and dementia. Depending on such risk factors and related symptoms, certain treatments can be utilized to help manage and slow disease progression. Do you know the risk factors, symptoms, and potential treatments for Alzheimer's disease? Test your knowledge with this quick quiz. Midlife hypertension is an established risk factor for Alzheimer-type dementia. Further, a brain autopsy study evaluating the link between hypertension and Alzheimer's disease found that patients using beta-blockers to control blood pressure had fewer Alzheimer-type brain lesions on autopsy compared with patients taking no drug therapy. Other risk factors for Alzheimer-type dementia include: Advancing age Family history APOE4 genotype genotype Obesity Insulin resistance Vascular factors Dyslipidemia Inflammatory markers Down syndrome Traumatic brain injury Caffeine is generally not a recognized risk factor for Alzheimer-type dementia or Alzheimer's disease. In fact, some studies have demonstrated a lower incidence of Alzheimer's disease in patients who consume caffeinated coffee. Similarly, moderate alcohol consumption is generally not recognized as a risk factor. In the 1960s and 1970s, exposure to aluminum was thought to be a possible risk factor for the development of Alzheimer's disease, leading to concerns about the use of cookware, antiperspirants, foil, antacids, and beverage cans in everyday life. Although studies have shown the neurotoxic effects of aluminum, particularly via exposure through dietary sources, they have failed to confirm a direct correlation between aluminum exposure and the development of Alzheimer's disease. Learn more about the risk factors for Alzheimer's disease. A 2025 report from the Alzheimer's Association indicated that older Black males and females are twice as likely to develop dementias, including Alzheimer's disease, compared with older White patients. Further, the same report noted that older Hispanic patients are at an increased risk for dementia and Alzheimer's disease when compared with older White, non-Hispanic patients. Specifically, the report states this population is 'one and one-half times as likely to have Alzheimer's or other dementias as White older adults.' Modifiable health factors include midlife obesity, which has been associated with the largest proportion of Alzheimer's disease cases in Black individuals, as well as physical inactivity. Additionally, cardiovascular and metabolic conditions, all of which elevate risk for dementia, disproportionately affect this demographic. Socioeconomic and psychosocial factors that correlate with dementia risk among older Black individuals include limited access to education, financial stability, and marital status. Missed and delayed diagnoses are more common in Black communities, and cultural bias in screening tools often leads to under-detection. Learn more about the epidemiology of Alzheimer's disease. By the time Alzheimer's disease reaches the moderate stage, damage has spread further to the areas of the cerebral cortex that control language, reasoning, sensory processing, and conscious thought. Affected regions continue to atrophy, making signs and symptoms of the disease more prominent, particularly as they relate to memory, judgment, and impulse control. The symptoms of this stage are typically: Increasing memory loss and confusion Shortened attention span Problems recognizing friends and family members Difficulty with language; problems with reading, writing, and working with numbers Difficulty organizing thoughts and thinking logically Inability to learn new things or to cope with new or unexpected situations Restlessness, agitation, anxiety, tearfulness, and wandering, especially in the late afternoon or at night Repetitive statements or movement, and occasional muscle twitches Hallucinations, delusions, suspiciousness or paranoia, and irritability Loss of impulse control (shown through such behavior as undressing at inappropriate times or places or using vulgar language) Perceptual motor problems (such as trouble getting out of a chair or setting the table) Pyramidal tract lesions, also known as upper motor neuron lesions, cause a wide range of motor deficits, including hyperactive reflexes, a positive Babinski sign (toe extension when stroking the sole of the foot), and spasticity. These can occur from any damage to the brain or spinal cord as a result of a stroke, trauma, tumors, meningitis, multiple sclerosis, or neurodegenerative disease, such as amyotrophic lateral sclerosis. While these lesions do occasionally occur in patients with Alzheimer's disease, their appearance is uncommon in this patient population. Hypothyroidism and hyperthyroidism can affect cognitive function and should be assessed during the initial workup for Alzheimer's disease. Although it is possible for either one to co-occur in patients, neither is a common symptom of moderate-stage disease. Seizures are not a common symptom associated with moderate Alzheimer's disease but are possible, particularly in late-stage disease and are potentially owing to poor disease course. Learn more about the clinical presentation of Alzheimer's disease. Structural neuroimaging with MRI (or noncontrast CT) to detect lesions that might cause cognitive impairment (eg, stroke, small vessel disease, and tumor) is typically most appropriate during the initial evaluation of patients with dementia or Alzheimer's disease. Imaging studies are part of initial diagnosis and are particularly important to assess for and rule out potentially treatable causes of progressive cognitive decline, such as chronic subdural hematoma or normal pressure hydrocephalus. Brain scanning with single-photon emission CT or PET is usually not recommended for the workup of patients with typical presentations of Alzheimer's disease. EEG is also not generally recommended but is valuable when Creutzfeldt-Jakob disease or another prion-related disease is a likely diagnosis. However, imaging studies are no longer the only method used in the initial evaluation of patients suspected of having Alzheimer's disease. In May 2025, the FDA approved the use of the Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio for the early detection of amyloid plaques associated with Alzheimer's disease in adult patients, aged 55 years and older, who are exhibiting signs and symptoms of the disease. Although not intended as a stand-alone diagnostic test, it serves as an additional resource to clinicians in a specialized setting as a less invasive diagnostic option. The test increases diagnostic accessibility to patients who might not have easy access to imaging. Learn more about the workup of Alzheimer's disease. Early detection combined with timely treatment enables patients with Alzheimer's disease to preserve their cognition and functional capacities at optimal levels. Cholinesterase inhibitors, along with mental exercises, are prescribed to help prevent or delay the deterioration of cognition in patients with Alzheimer's disease. Cholinesterase inhibitors that have been approved in the US and Europe for the treatment of Alzheimer's disease include donepezil, galantamine, and rivastigmine. Further, certain antiamyloid monoclonal antibody treatments have been approved to slow disease progression as well. According to the Alzheimer's Association, nonpharmacological treatments used to initially and routinely manage symptoms include 'physical activity, reminiscence exercises, music ‐ and art ‐ based therapies, pet therapy, and light therapy.' Some studies suggest that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) might have a protective effect against Alzheimer's disease, potentially through their anti-inflammatory effects and possible ability to reduce amyloid. However, findings from observational studies and short-term randomized controlled trials have been mixed, and optimal dosage and duration of (NSAIDs) for this purpose remain unclear. Studies suggest that long-term (but not cumulative) use of NSAIDs might be associated with decreased dementia risk. However, further investigation is warranted. Neuroleptic agents are not generally used to prevent or delay deterioration of cognition in patients with Alzheimer's disease. Some data have indicated that they are linked to an increased risk of cognitive decline. While some studies have shown that vitamin E can reduce amyloid-beta oxidative stress, as well as improve memory and cognitive deficits, conflicting results were noted in clinical trials assessing the efficacy of vitamin E as a preventive or treatment for Alzheimer's disease. Further, they are not typically used as an initial therapy to prevent or delay deterioration of cognition in patients with Alzheimer's disease. Learn more about the treatment and management of Alzheimer's disease.
Fox News
2 hours ago
- Fox News
ChatGPT could be silently rewiring your brain as experts urge caution for long-term use
Using ChatGPT on a long-term basis could have negative effects on brain function. That's according to a study led by the Massachusetts Institute of Technology (MIT), which found that using a large language model (LLM) to write multiple essays over a four-month period could hamper cognitive abilities. In the study, 54 participants were divided into three groups. One group used ChatGPT, an LLM product made by OpenAI, to write an essay. The second group used only a search engine, and the third group used only their own brains, according to a press release from MIT. The participants underwent three sessions where they completed the same assignment. Then, in the fourth session, the LLM group was asked to write an essay without any tools, and the "brain-only" group was asked to use an LLM for assistance. During each session, the researchers recorded the participants' brain activity using an EEG monitor to assess their "cognitive engagement and cognitive load" and to determine their neural activity, the release stated. The participants also provided their own individual feedback during interviews. Human teachers and an artificial intelligence agent scored the assessments. "EEG analysis presented robust evidence that LLM, search engine and brain-only groups had significantly different neural connectivity patterns, reflecting divergent cognitive strategies," the researchers wrote. Participants showed less brain connectivity when they used the tools to help write their essays, the study found. "The brain‑only group exhibited the strongest, widest‑ranging networks; the search engine group showed intermediate engagement; and LLM assistance elicited the weakest overall coupling," the researchers wrote. "The key isn't avoiding AI — it's building cognitive strength first." In the fourth session, the participants who switched from LLM to brain-only showed "weaker neural connectivity" and less cognitive engagement. The LLM group also had less ability to recall information from the essays they had just written. Those who switched from brain-only to LLM had "higher memory recall" and greater cognitive engagement. Based on these findings, the researchers said there could be a "possible decrease in learning skills" among LLM users. "The use of LLM had a measurable impact on our participants, and while the benefits were initially apparent, as we demonstrated over the course of four sessions … the LLM group's participants performed worse than their counterparts in the brain-only group at all levels: neural, linguistic [and] scoring," they wrote. The findings have been uploaded to Arxiv, a preprint service, but have not yet been peer-reviewed, as the researchers noted that "all conclusions are to be treated with caution and as preliminary." There were also a limited number of participants who were all from the same geographical area. "For future work, it will be important to include a larger number of participants coming from diverse backgrounds, like professionals in different areas and age groups, as well as ensure that the study is more gender-balanced," the researchers noted. Only ChatGPT was used in the study; future research could incorporate other LLMs. The EEG technology used to analyze brain connectivity could also have some limitations, as the researchers shared plans to use fMRI (functional magnetic resonance imaging) in future studies. "Our findings are context-dependent and are focused on writing an essay in an educational setting and may not generalize across tasks," they also stated. "Future studies should also consider exploring longitudinal impacts of tool usage on memory retention, creativity and writing fluency." Dr. Harvey Castro, an ER physician and "AI futurist" based in Texas, said he sees this study as a "neuro-wake-up call," especially for younger brains. "ChatGPT can make you 60% faster, but that speed comes at the price of neuro-engagement," Castro, who was not involved in the study, told Fox News Digital. "Brain connectivity collapses from 79 neural links to just 42, and 83% of users can't quote their own essays minutes later. Neuroplasticity research tells us developing brains will feel this hit hardest." In emergency medicine, Castro said, doctors call this "failure to encode." "The brain isn't processing and storing information," he said. "When neural connectivity drops by nearly half, we're looking at what researchers call 'cognitive debt.'" For medical students, an inability to encode and recall information under pressure could have serious implications for clinical decision-making, Castro noted. "The same neural networks that consolidate essay information are involved in diagnostic reasoning," he said. Using LLMs for extended periods can be convenient, but could cause cognitive muscles to "atrophy" over time, the expert cautioned. There was one encouraging finding, however. "When people with strong foundational skills later used ChatGPT, they showed enhanced connectivity," Castro said. "The key isn't avoiding AI — it's building cognitive strength first." In education, he emphasized the need for periods of "AI-free cognitive development." For more Health articles, visit "Sometimes you act on preliminary data when the stakes are high enough, and an entire generation's brain development is high stakes." Fox News Digital reached out to OpenAI for comment.
